Perrigo (PRGO)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$15.83+0.83%
Close 2026-11-04 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
QuarterlyIQ Insights · PRGO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -22.5% |
| Our one-year growth estimate | diamond | -0.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 22.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 8 industry peers · Company calendar date is not available
PRGO — CEO transition
Dated 2026-07-06
Interim President and Chief Executive Officer — Albert A. Manzone: Mr. Manzone was appointed as the Interim President and Chief Executive Officer with detailed compensatory arrangements.
Why it matters: Perrigo used most Dermacosmetics cash proceeds to cut debt. Debt stood at $3.3 billion in Q2; another drop would show that debt reduction continues.
Supportive ifA later report shows total debt below $3.3 billion, with sale proceeds or other cash used to repay debt.
Worry ifTotal debt rises above $3.3 billion, or the company reports no more debt cuts.
Why it matters: Perrigo plans a non-cash charge of $275 million to $375 million in Q4. The reported charge will show whether it falls within that range.
Worry ifPerrigo reports a Q4 2026 non-cash charge of $275 million to $375 million. The charge is tied to the Infant Formula sale.
Less concerning ifPerrigo reports no Q4 charge, or a charge below $275 million tied to the sale.
Why it matters: The sale is set to close in the first half of 2027. Closing would remove the business and its planned capital needs; delays could put that plan at risk.
Watch forPerrigo reports the sale to MeridianMade closed by June 30, 2027. It got the required approvals first.
Also watch forPerrigo reports an approval failed, the sale ended, or it did not close by June 30, 2027.
Why it matters: Core adjusted operating margin fell to 13.0% in Q2, from 14.6% a year earlier. A recovery would show that cost cuts and better volume are helping.
Watch forCore adjusted operating margin tops 13.0% in a later quarter. It is also higher than a year ago.
Also watch forCore adjusted operating margin falls below 13.0%, or stays below its level from a year ago.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$157 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $453 loss on $10,000 · 4.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,209 loss on $10,000 · 52.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Core sales fell 3.1% in Q2, as shoppers bought less and retail stocks stayed low. A return to growth would show demand is improving.
Watch forQuarterly Core net sales rise year over year, after falling 3.1% in Q2 2026.
Also watch forQuarterly Core net sales fall more than 3.1% year over year, or retail inventory levels keep dropping.
Why it matters: Perrigo kept its full-year outlook after Q2, despite lower Core sales and margins. Q3 results can show whether the planned second-half gains are taking hold.
Watch forOn November 4, Perrigo confirms its 2026 outlook. Core sales or adjusted operating margin falls less than Q2's year-over-year drops of 3.1% and 160 basis points.
Also watch forPerrigo cuts its 2026 outlook. Or Q3 Core sales and adjusted operating margin fall further from a year ago.